

# SHYCOCAN™

## ATTENUATION/DISABLING OF CORONAVIRUSES\* INCLUDING THE VIRUS ASSOCIATED WITH COVID-19

**Scalene Hypercharge Corona Canon (SHYCOCAN™)**, is intended for real-time attenuation and disabling of certain viruses, including coronaviruses - the virus associated with COVID-19, and the elimination of expected viral loads of Influenza B. This device is a simple, portable, and sensitive methodology intended to disable air and surface borne coronaviruses. Exposure to atmospheric and surface contamination of SARS-CoV-2 can randomly occur. The SHYCOCAN technology is intended to inactivate coronaviruses in the air and on surfaces.

The negative charge-seeking guidance mechanism of the virus' Spike Protein can be disabled and neutralized by trillions of electrons generated per second by the SHYCOCAN™. High-intensity discharge of electrons relies on precision design and geometry of the proprietary Photon-Mediated Electron Emitters (PMEE) in the device. This unique and innovative device can be readily and cost-effectively manufactured to meet demand.

**Note:** For detailed information, market-specific questions and FAQs, please visit [www.shreis.org](http://www.shreis.org)



*SHYCOCAN™ Device with proprietary Photon-Mediated Electron Emitters (PMEEs) behind porous safety shielding*

### FEATURES & BENEFITS

- ✓ **99.994% (>4Log<sub>10</sub>) reduction** in a standard decontamination assay with Bacteriophage MS2
- ✓ **\*99.963% reduction of an EPA-standard SARS-CoV-2 surrogate** coronavirus, in BSL-2 facilities<sup>1</sup>
- ✓ **Elimination of expected Influenza B viral loads**, in BSL-2 facilities<sup>1</sup>
- ✓ **\*SARS-CoV-2 assays in enhanced BSL-2 and BSL-3 facilities currently underway**
- ✓ 510K Compilation in Process
- ✓ **EU-CE Marked and safety certified (Class 1 Device)**
- ✓ Intended for use with people in the room
- ✓ Novel technology without ozone emission, use of chemicals, ultraviolet light, ionization, or plasma generation
- ✓ **Spatial coverage per device up to 1000 ft<sup>2</sup> / 10,000 ft<sup>3</sup>**
- ✓ Bacteria, fungi, or other eco-friendly micro-organisms are not targeted, intended for **24/7 deployment** in the home environment with pets, plants etc.
- ✓ Intended for use in commercial, corporate, educational, faith-based, healthcare, medical, industrial, mass transit, residential settings etc.
- ✓ Instantaneous electron release on the switch of a button like when a light is turned on in a room
- ✓ Plug and play device with no setup required except for mounting on a wall, pedestal or table-top
- ✓ Can be run continuously and operates on standard 110/240v wall outlets. No additional consumables required
- ✓ Intended for over-the-counter use
- ✓ One-year warranty for manufacturing defects

### ABOUT SHREIS

**Shreis Scalene Group of LLCs** - Shreis Scalene Therapeutics LLC prioritized the [SHYCOCAN™](#) device project intended to deactivate certain viruses, including coronaviruses, the virus associated with COVID-19. The Shreis Scalene Group of Therapeutic and Diagnostic medical device companies is head-quartered in Montgomery County, MD, USA. Together with the Inventor and Technology partner, Dr. Rajah Vijay Kumar, the Shreis Scalene Group is bringing novel, non-invasive, engineering solutions to human health problems. These include the [CYTOTRON®](#) with US-FDA Breakthrough Designation granted for solid tumors of the Breast, Liver and Pancreas (among other solid tumors clinically validated in off-shore clinical studies); tissue regeneration (in musculoskeletal disorders, degenerative respiratory disorders, wound healing etc.); the [CELLFORN®](#) for safe, non-invasive cancer drug delivery, and the [HAEMOSEIS-256®](#) - a diagnostic cardiovascular disease detection device; for North and South American markets, including Mexico and the Caribbean. Shreis' mission is to introduce leading-edge platform technologies that will impact the survivorship experience with quality of life, and continue to offer global solutions for safer, patient-centric, affordable healthcare.

<sup>1</sup>Peer-reviewed publication in progress.

© Copyright 11/2020 Shreis Scalene Therapeutics LLC. All rights reserved. All specifications are subject to change without notice.